Beijing Beilu Pharmaceutical Co., Ltd. (300016) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Beilu Pharmaceutical Co., Ltd.

Why is Beijing Beilu Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 6.13% and Operating profit at -22.42% over the last 5 years

With a growth in Net Sales of 5.79%, the company declared Very Positive results in Sep 25

OPERATING CASH FLOW(Y) Highest at CNY 176.47 MM
NET SALES(9M) At CNY 872.68 MM has Grown at 21.13%
NET PROFIT(HY) Higher at CNY 25.38 MM

With ROE of 0.93%, it has a expensive valuation with a 2.89 Price to Book Value

Over the past year, while the stock has generated a return of 31.06%, its profits have risen by 134.6% ; the PEG ratio of the company is 2.3
At the current price, the company has a high dividend yield of 0.5

Market Beating performance in long term as well as near term

Along with generating 31.06% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Beilu Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Beilu Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Beilu Pharmaceutical Co., Ltd.

31.06%

1.65

58.76%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.13%

EBIT Growth (5y)

-22.42%

EBIT to Interest (avg)

2.51

Debt to EBITDA (avg)

0.83

Net Debt to Equity (avg)

0.16

Sales to Capital Employed (avg)

0.37

Tax Ratio

100.00%

Dividend Payout Ratio

179.86%

Pledged Shares

Institutional Holding

ROCE (avg)

3.85%

ROE (avg)

2.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

309

Industry P/E

Price to Book Value

2.89

EV to EBIT

98.25

EV to EBITDA

33.12

EV to Capital Employed

2.58

EV to Sales

4.85

PEG Ratio

2.30

Dividend Yield

0.50%

ROCE (Latest)

2.63%

ROE (Latest)

0.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 176.47 MM

NET SALES(9M)

At CNY 872.68 MM has Grown at 21.13%

NET PROFIT(HY)

Higher at CNY 25.38 MM

ROCE(HY)

Highest at 1.72%

PRE-TAX PROFIT(Q)

At CNY 9.4 MM has Grown at 151.72%

DEBT-EQUITY RATIO (HY)

Lowest at -5.81 %

-4What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.9 times

OPERATING PROFIT(Q)

Lowest at CNY 9.22 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 3.2 %

Here's what is working for Beijing Beilu Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 176.47 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

At CNY 9.4 MM has Grown at 151.72%

over average net sales of the previous four periods of CNY 3.73 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

Higher at CNY 25.38 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Sales

At CNY 872.68 MM has Grown at 21.13%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Debt-Equity Ratio

Lowest at -5.81 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Beijing Beilu Pharmaceutical Co., Ltd.

Debtors Turnover Ratio

Lowest at 5.9 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Profit

Lowest at CNY 9.22 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 3.2 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales